Tuning Up Part D Amid Drug Pricing Debate; MedPAC Likely To Urge More Flexibility For Plans Setting Formularies
This article was originally published in RPM Report
Executive Summary
The Medicare Payment Advisory Committee (MedPAC) will be moving forward with specific recommendations to improve prescription drug provisions under Part D and Part B – but is not ready to take the lead on policy development addressing prescription drug prices overall.
You may also be interested in...
340B Drug Discount Program Hits A Turning Point, But In Which Direction?
Long-awaited “mega-guidance” sets boundaries on discount and makes big changes for HIV drugs – and could mean the beginning of the end of the scrutiny of the program. A legislative proposal floated in the context of the “21st Century Cures” bill might move things in a different direction.
Autism Feedback To FDA: Focus On Communication, Redefine 'Irritability'
US FDA’s 22nd Patient-Focused Drug Development meeting focused on the challenging disease of autism. It also showed how far FDA has come in embracing the patient-input process over the past five years.
SMA Patient Meeting Showcases FDA Flexibility – And Appreciation From Advocates
US agency's top neurology review officials received warm reception during Patient Focused Drug Development meeting for Spinal Muscular Atrophy. They also delivered a strong message of continued engagement beyond the first drug approval.